T2 Biosystems Praises CDC's Actions Aimed At Optimizing U.S. Hospital Sepsis Programs
Portfolio Pulse from Happy Mohamed
T2 Biosystems, Inc. (NASDAQ:TTOO) has praised the U.S. Centers for Disease Control and Prevention's (CDC) new Hospital Sepsis Program Core Elements, aimed at improving sepsis programs and survival rates in U.S. hospitals. T2 Biosystems' products, including the T2Dx® Instrument, the T2Bacteria® Panel, and the T2Candida® Panel, are the first and only FDA-cleared products able to detect sepsis-causing pathogens directly from whole blood in 3-5 hours. The company's products identified sepsis-causing pathogens 77 hours faster than blood culture-based protocols, according to a meta-analysis of 14 controlled studies.
August 28, 2023 | 12:37 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
T2 Biosystems' products, which can detect sepsis-causing pathogens directly from whole blood in 3-5 hours, could see increased demand following the CDC's new Hospital Sepsis Program Core Elements. The company's products identified sepsis-causing pathogens 77 hours faster than blood culture-based protocols.
The CDC's new Hospital Sepsis Program Core Elements could lead to increased demand for T2 Biosystems' products, which can detect sepsis-causing pathogens directly from whole blood in 3-5 hours. This is significantly faster than blood culture-based protocols, which could make T2 Biosystems' products more attractive to hospitals looking to improve their sepsis programs.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100